pharmacopeia
GET
/api/v1/drug/triamcinolone
2D structure
(8S,9R,10S,11S,13S,14S,16R,17S)-9-fluoro-11,16,17-trihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-3-one
SMILES C[C@]12C[C@@H]([C@]3([C@H]([C@@H]1C[C@H]([C@@]2(C(=O)CO)O)O)CCC4=CC(=O)C=C[C@@]43C)F)O
InChIKey GFNANZIMVAIWHM-OBYCQNJPSA-N

Mechanism of action

Sourced from openFDA

Mechanism-of-action classes: Corticosteroid Hormone Receptor Agonists; Glucocorticoid Receptor Agonists; Lipoxygenase Inhibitors.

Corticosteroid Hormone ReceptorGlucocorticoid ReceptorLipoxygenase

Indications

Sourced from openFDA
  • & USAGE Topical corticosteroids are indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses.

Contraindications

Sourced from openFDA
  • Topical corticosteroids are contraindicated in those patients with a history of hypersensitivity to any of the components of the preparation.contraindicated

Dosage & administration

Sourced from openFDA

DOSAGE & ADMINISTRATION Topical corticosteroids are generally applied to the affected area as a thin film two to four times daily for the 0.025% strength and two or three times daily for the 0.1% and 0.5% strength depending on the severity of the condition. Occlusive dressings may be used for the management of psoriasis or recalcitrant conditions. If an infection develops, the use of occlusive dressings should be discontinued and appropriate antimicrobial therapy instituted.

Adverse reactions

Sourced from openFDA

The following local adverse reactions are reported infrequently with topical corticosteroids, but may occur more frequently with the use of occlusive dressings. These reactions are listed in an approximate decreasing order of occurrence: burning, itching, irritation, dryness, folliculitis, hypertrichosis, acneiform eruptions, hypopigmentation, perioral dermatitis, allergic contact dermatitis, maceration of the skin, secondary infection, skin atrophy, striae, and miliaria.

Use in specific populations

Sourced from openFDA

PREGNANCY CATEGORY C Corticosteroids are generally teratogenic in laboratory animals when administered systemically at relatively low dosage levels. The more potent corticosteroids have been shown to be teratogenic after dermal application in laboratory animals. There are no adequate and well-controlled studies in pregnant women on teratogenic effects from topically applied corticosteroids. Therefore, topical corticosteroids should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. Drugs of this class should not be used extensively on pregnant patients, in large amounts, or for prolonged periods of time.

Overdosage

Sourced from openFDA

Topically applied corticosteroids can be absorbed in sufficient amounts to produce systemic effects (See PRECAUTIONS ).

Approval history

Sourced from openFDA
  • Jan 4, 1960NDANDA012041Apothecon
  • Feb 1, 1965NDANDA014901Apothecon
  • Mar 9, 1978ANDAANDA085691Fougera Pharms
  • Mar 9, 1978ANDAANDA085692Fougera Pharms
  • May 20, 1996NDANDA020468Chattem Sanofi
  • Nov 29, 2007NDANDA022048Harrow Eye
  • Oct 6, 2017NDANDA208845Pacira Pharms Inc
  • Oct 22, 2021NDANDA211950Bausch And Lomb Inc

FAERS reports

View JSON
Reference statistics only. FAERS reports are voluntarily submitted and are not incidence rates, safety signals, or causal evidence. Counts reflect reporting volume — how often a reaction was reported, not how often it occurs. For decision-grade use, consult openFDA and the FAERS Public Dashboard directly.
30,526 total reports matchedLatest report Share = reports listing the reaction ÷ total matched reports. Rows can sum to >100% because a single report often lists multiple reactions.
  1. 1Drug Ineffective5,25217%
  2. 2Off Label Use2,8159.2%
  3. 3Pruritus2,3917.8%
  4. 4Rash2,3477.7%
  5. 5Pain2,1307.0%
  6. 6Fatigue2,0386.7%
  7. 7Nausea2,0236.6%
  8. 8Headache1,8386.0%
  9. 9Condition Aggravated1,7445.7%
  10. 10Diarrhoea1,7145.6%
  11. 11Product Use In Unapproved Indication1,6845.5%
  12. 12Vomiting1,6845.5%
  13. 13Dizziness1,5905.2%
  14. 14Arthralgia1,5695.1%
  15. 15Malaise1,3794.5%

Literature

View JSON

Recent PubMed references pinned to Triamcinolone as a MeSH major topic. Citations link to pubmed.ncbi.nlm.nih.gov.

Clinical trials

View JSON

The 10 most recently updated of 1,111 ClinicalTrials.gov registrations naming Triamcinolone as an intervention. Registration is not evidence of efficacy or safety — reference crosswalk only.

Pharmacogenomics

View JSON

CPIC-curated drug–gene pairs for Triamcinolone. Levels describe the strength of curated evidence and guideline status — never a recommendation to test or to adjust therapy.

  • CRHR1CPIC D (provisional)

Structural analogs

View JSON

Ranked by 2D fingerprint (Tanimoto) similarity over PubChem structures. Structural proximity only — not a claim of therapeutic equivalence.

Frequently asked questions

How does Triamcinolone work?
Mechanism-of-action classes: Corticosteroid Hormone Receptor Agonists; Glucocorticoid Receptor Agonists; Lipoxygenase Inhibitors.
What is Triamcinolone used for?
According to FDA labeling, Triamcinolone carries indications including: & USAGE Topical corticosteroids are indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses.. This is a reference summary of labeled uses, not medical advice or a treatment recommendation.
What class of drug is Triamcinolone?
Triamcinolone is classified as Corticosteroids, Corticosteroids for local oral treatment, Corticosteroids, moderately potent (group II), Corticosteroids, moderately potent, other combinations, Corticosteroids, plain, Glucocorticoids, Corticosteroid, Corticosteroid Hormone Receptor Agonists, Glucocorticoid Receptor Agonists, Lipoxygenase Inhibitors, Carbohydrate Metabolism Alteration, Decreased Capillary Permeability, Decreased Cytokine Activity, Decreased Fibroblast Migration, Decreased Glucocorticoid Secretion, Decreased Leukotriene Activity, Decreased Polymorphonuclear Leukocyte Migration, Decreased Prostaglandin Activity, Decreased Protein Synthesis, Decreased Thromboxane Activity, Lipid Metabolism Alteration, Lysosomal Function Alteration.
What are the brand names for Triamcinolone?
Triamcinolone is marketed under brand names including Aller-Cort, AllerNaze, Genesis, Hexatrione, Kenalog, Kourzeq, Nasacort, Oralone.
What are the contraindications for Triamcinolone?
Triamcinolone labeling lists contraindications including: Topical corticosteroids are contraindicated in those patients with a history of hypersensitivity to any of the components of the preparation.. Always consult the full prescribing information and a clinician.
Note. Data for triamcinolone is illustrative MVP content compiled from public sources. pharmacopeia is for educational and informational use only and is not a substitute for professional medical advice.

Search pharmacopeia

Search drugs, classes, and ingredients